Hereditary ATTRV30M amyloidosis is a genetic disease in which a change (mutation) in the transthyretin (TTR) gene—most often the Val30Met variant—causes the TTR protein to become unstable, break apart, and form amyloid deposits. These deposits build up in nerves, the heart, eyes, kidneys, and other tissues. The disease commonly starts with numbness and burning pain in the feet and legs, then spreads upward, and may also involve fainting, diarrhea or constipation, weight loss, and later heart problems. It is usually inherited in an autosomal dominant way, but the age at which symptoms start (penetrance) varies by family and region. NCBI+2PMC+2

Normal TTR is a four-part (tetramer) protein that carries thyroid hormone and retinol-binding protein. In Val30Met, the tetramer more easily falls apart into monomers that misfold and form amyloid fibrils. Fibrils damage small and large nerve fibers and can stiffen the heart muscle. The rate-limiting step is tetramer dissociation; stabilizing the tetramer or reducing TTR production slows disease. Nature

Hereditary ATTRV30M amyloidosis is a genetic disease. It happens when a protein called transthyretin (TTR), made mostly by the liver, changes shape and sticks together as long strands called amyloid. These strands deposit in nerves, the heart, the gut, the eyes, and other organs. The specific genetic change here is Val30Met (V30M) in the TTR gene. Over time, these deposits damage the nerves (causing numbness, pain, weakness, and autonomic problems like dizziness on standing or stomach issues) and can also affect the heart and other organs. The condition is autosomal dominant, which means a child of an affected parent has a 50% chance to inherit the variant. Onset and severity vary by family and region. NCBI+2PMC+2

Other names

People may call this condition by several names:

• Hereditary transthyretin amyloidosis (ATTRv)

• Familial amyloid polyneuropathy (FAP) due to V30M

• ATTR Val30Met amyloidosis

• hATTR polyneuropathy (Val30Met subtype)
  All of these refer to TTR amyloid disease caused by the Val30Met variant, most often presenting with progressive nerve and autonomic symptoms, sometimes with heart, eye, or kidney involvement. NCBI+1

Types

Doctors often group ATTRV30M disease by the main organ involved and by age at onset, because these patterns guide testing and care:

1. Neuropathy-predominant type – Most common with V30M. It starts as a length-dependent neuropathy: tingling, burning pain, numbness in the feet, then legs and hands, plus autonomic symptoms (bowel changes, dizziness on standing, erectile dysfunction). NCBI+2PMC+2

2. Mixed (neuro-cardiac) type – Nerve symptoms plus signs of heart involvement, like shortness of breath, leg swelling, or abnormal heart tests. This is seen more often in later-onset V30M and in some non-endemic regions. PMC+1

3. Cardiac-dominant type – The heart is the main organ affected (stiff heart, arrhythmias), with mild or late neuropathy. This pattern is less typical for early-onset V30M, but may appear with late onset. AHA Journals

4. Early-onset V30M (endemic areas) vs Late-onset V30M (non-endemic areas) – Early onset (often 20s–40s) in places like Portugal and Japan is classically neuropathy-dominant with strong autonomic features. Late-onset cases (often after age 50) may have more motor neuropathy and more frequent cardiac involvement. NCBI+1

---

Causes

Important note: The direct cause is the TTR Val30Met variant. The other items below are contributors or modifiers that research and clinical experience suggest can influence when symptoms start, which organs are affected, and how fast the disease progresses. They do not “cause” amyloidosis by themselves; the genetic variant is the root cause.

1. TTR Val30Met (V30M) variant – This specific change makes TTR less stable, so it misfolds and forms amyloid fibrils that deposit in tissues. NCBI

2. Autosomal-dominant inheritance – Children of an affected parent have about a 50% chance to inherit V30M; penetrance (chance to develop disease if you carry the variant) varies. NCBI

3. Age – The longer we live, the more time misfolded proteins have to accumulate, so symptoms often appear in adulthood and may come earlier in endemic areas or later elsewhere. NCBI

4. Geographic founder effects – In some regions (e.g., parts of Portugal, Sweden, Japan) V30M is more common, and family patterns influence age at onset and presentation. NCBI

5. Genetic background/penetrance modifiers – People with the same V30M variant can have different ages of onset and organ patterns, likely due to other genes and modifiers. PMC

6. Protein homeostasis (proteostasis) stress – General stress on the body’s protein-folding and cleanup systems (aging, illnesses) can favor amyloid buildup over time. (Inference consistent with amyloid biology.) PMC

7. Liver production of TTR – Most TTR is made in the liver; the constant supply of variant TTR allows ongoing amyloid formation unless treated. NCBI

8. Autonomic neuropathy itself – Once nerves are injured and blood flow/regulation change, symptoms can worsen and spread, creating a cycle of disability. PMC

9. Late-onset phenotype factors – Later-onset V30M cases often show more motor neuropathy and more heart involvement than early-onset cases. PMC

10. Male sex predominance in some cohorts – Some series report more affected males or earlier male onset in certain regions (pattern varies by population). PMC

11. Cardiac stressors with aging – Stiffer heart muscle and other age-related changes may unmask cardiac involvement in late-onset V30M. AHA Journals

12. Co-existing conditions – Diabetes, malnutrition, or chronic illnesses can worsen nerve and heart function and amplify symptoms, even though they don’t cause the amyloid. (General clinical inference supported by neuropathy/heart literature.) PMC

13. Nutritional deficiency/weight loss – Amyloid neuropathy often causes early satiety and diarrhea, which can worsen weakness and frailty, increasing disability. PMC

14. Inflammatory states/illness – Illnesses may temporarily worsen autonomic symptoms (e.g., blood pressure drops on standing). (Clinical observation consistent with autonomic neuropathy.) PMC

15. Eye involvement – Local eye production of TTR (in the retina/ciliary body) can lead to ocular amyloid even after liver-targeted treatments; eye disease can add disability. NCBI

16. Kidney involvement – Protein in urine and kidney strain add fatigue and swelling, worsening overall health. NCBI

17. Carpal tunnel syndrome – Median nerve compression can precede or accompany neuropathy and increase hand disability. PMC

18. Autonomic GI dysfunction – Chronic diarrhea/constipation and malabsorption accelerate weight loss and frailty. PMC

19. Conduction disease/arrhythmias – Amyloid in the heart’s electrical system causes dizziness, fainting, and fatigue, compounding nerve symptoms. AHA Journals

20. Diagnostic delay – The disease is rare and often misdiagnosed; delayed diagnosis allows more amyloid to accumulate and more damage to occur. ScienceDirect

---

Common symptoms

1. Tingling, burning, or numbness in the feet – This is a “length-dependent” nerve problem that climbs from feet to legs and hands. NCBI

2. Shooting or burning pain – Due to small-fiber nerve injury; pain can be severe and disturb sleep. Frontiers

3. Weakness in legs and hands – As larger nerves are damaged, walking, climbing stairs, and fine hand tasks get hard. NCBI

4. Balance problems – Loss of joint-position sense and weakness cause unsteady walking and falls. Frontiers

5. Dizziness on standing (orthostatic hypotension) – Autonomic nerves cannot maintain blood pressure when you stand up, so you feel faint. PMC

6. Bowel changes – Alternating diarrhea and constipation are typical; diarrhea can be watery and frequent. PMC

7. Nausea, early fullness, weight loss – Stomach emptying slows; weight drops over months. PMC

8. Erectile dysfunction or sexual dysfunction – Very common sign of autonomic nerve injury. PMC

9. Reduced sweating, dry eyes/mouth – Part of autonomic involvement. PMC

10. Shortness of breath or swelling of legs – Possible heart involvement (stiff heart, fluid buildup). AHA Journals

11. Heart rhythm problems – Palpitations, lightheadedness, or fainting due to conduction disease. AHA Journals

12. Carpal tunnel symptoms – Numbness and tingling in the thumb, index, and middle fingers; often both hands. PMC

13. Eye floaters or vision changes – Vitreous opacities and other ocular issues may appear. NCBI

14. Kidney problems – Protein in urine or reduced kidney function can develop. NCBI

15. General tiredness and weakness – Due to nerve damage, poor nutrition, and sometimes heart or kidney involvement. PMC

---

Diagnostic tests

A) Physical examination (bedside checks)

1. Neurologic exam – The doctor checks sensation (pin, temperature, vibration), strength, and reflexes to map the neuropathy pattern typical of ATTRV30M. NCBI

2. Autonomic signs – Blood pressure and heart rate measured lying and standing can show orthostatic hypotension (big BP drop on standing). PMC

3. Heart and fluid exam – Listening for extra heart sounds and looking for leg swelling can suggest cardiac involvement. AHA Journals

4. Hand/wrist exam – Tapping or pressing over the carpal tunnel may reproduce tingling, suggesting co-existing carpal tunnel syndrome. PMC

5. Eye exam basics – Noting floaters or reduced vision prompts a more detailed eye evaluation for vitreous opacities. NCBI

B) Manual/bedside tests (simple provocation or clinic tools)

6. Orthostatic vital testing – Measuring BP/HR after lying, then standing for 1–3 minutes; a large BP drop supports autonomic failure. PMC

7. Bedside sensory testing – Cotton, pin, tuning fork (128 Hz vibration) help document length-dependent sensory loss. NCBI

8. Bedside heart rhythm check – Pulse irregularity may suggest conduction disease and prompt ECG and monitoring. AHA Journals

9. Nutritional screen (weight/BMI) – Ongoing weight loss is common in neuropathy-predominant ATTRV30M and guides urgency of care. PMC

C) Laboratory and pathology tests

10. TTR gene testing (sequencing) – Confirms the Val30Met variant and distinguishes hereditary ATTR from other amyloidoses. This is definitive for the genetic cause. NCBI

11. Tissue biopsy with Congo red stain – Fat pad, nerve, salivary gland, or involved organ biopsy shows amyloid that glows apple-green under polarized light—this is the classic sign. PMC+1

12. Amyloid typing (immunohistochemistry or mass spectrometry) – Proves that the deposits are TTR and not light chain (AL) or another type; typing is crucial before treatment. PMC

13. Serum and urine studies to exclude AL – Tests such as serum free light chains and immunofixation help rule out light-chain amyloidosis, which changes the diagnostic pathway. PMC

14. Cardiac biomarkers (NT-proBNP, troponin) – Elevated levels suggest heart stress or damage from amyloid and guide further imaging. AHA Journals

15. Urine protein (24-hour or spot albumin/creatinine) – Detects kidney involvement, which can occur in hereditary ATTR. NCBI

D) Electrodiagnostic and autonomic function tests

16. Nerve conduction studies (NCS) and electromyography (EMG) – Show reduced nerve signals and help confirm length-dependent polyneuropathy typical of ATTRV30M. Frontiers

17. Autonomic reflex screen/QSART – Measures sweat output and reflexes of the autonomic nervous system; useful when dysautonomia is suspected. ScienceDirect

18. Tilt-table testing – Formal test for orthostatic hypotension and abnormal heart-rate responses caused by autonomic neuropathy. ScienceDirect

E) Imaging tests

19. Cardiac scintigraphy with 99mTc-PYP (or DPD/HMDP) – Bone-tracer scans that bind ATTR in the heart. In the absence of light-chain abnormalities, grade 2–3 uptake is highly specific for ATTR cardiomyopathy (ATTR-CM) and can allow non-biopsy diagnosis. SPECT improves accuracy. PMC+3AHA Journals+3PMC+3

20. Echocardiography with strain + Cardiac MRI – Echo may show thick walls and reduced longitudinal strain (apical sparing pattern). Cardiac MRI can show late gadolinium enhancement and difficulty “nulling” the myocardium, both supportive of amyloid. These tests assess severity and guide care. AHA Journals

Non-pharmacological treatments

1. Disease education & genetic counseling—helps families understand inheritance, testing, and early signs; improves timely care and surveillance. Mechanism: informed choices and earlier detection improve outcomes. BioMed Central

2. Structured exercise (aerobic + balance + strength)—improves function, gait, and balance in peripheral neuropathy conditions, even when QoL gains are modest; programs need supervision early and safety checks for orthostatic symptoms. Mechanism: neuroplasticity, muscle strength, and cardiovascular conditioning. PubMed+1

3. Falls prevention program—home hazard review, assistive devices, and balance training reduce falls in neuropathy and autonomic dysfunction. Mechanism: lowers fall risk from sensory loss and dizziness. NCBI

4. Physical therapy for gait training—task-specific training and ankle-foot orthoses help foot-drop and improve walking safety. Mechanism: compensates for distal weakness and proprioceptive loss. NCBI

5. Occupational therapy—modifies tools and activities (button hooks, grab bars) to maintain independence. Mechanism: reduces disability from hand numbness/weakness. NCBI

6. Compression stockings/garments—help orthostatic dizziness by improving venous return; waist-high garments work best. Mechanism: external compression reduces venous pooling. AAFP+1

7. Hydration and salt optimization (if no heart failure)—supports blood pressure in autonomic neuropathy; adjust carefully in cardiac involvement. Mechanism: expands intravascular volume. AAFP

8. Small, frequent meals—reduces post-meal blood pressure drops and GI symptoms. Mechanism: minimizes splanchnic pooling and glycemic swings. AAFP

9. Head-of-bed elevation—lessens nocturnal hypertension and morning orthostatic symptoms in autonomic failure. Mechanism: reduces nighttime diuresis. AHA Journals

10. Pain self-management skills—sleep hygiene, pacing, and mindfulness can complement analgesics. Mechanism: reduces central sensitization and distress. PubMed

11. Careful foot care—daily inspection, proper footwear, and podiatry decrease ulcer risk in sensory loss. Mechanism: prevents unnoticed injuries. NCBI

12. Dietary counseling for cardiac health—low-sodium diet for edema/heart symptoms (individualized with a clinician). Mechanism: reduces fluid retention. AHA Journals

13. Bowel regimen and nutrition—fiber, fluids, and scheduled toileting help constipation from autonomic neuropathy; nutrition support fights weight loss. Mechanism: motility support and caloric adequacy. NCBI

14. Hand/wrist splints for carpal tunnel—may ease nocturnal paresthesia; refer early if progressive. Mechanism: reduces median nerve compression. PMC

15. Eye care and early referral—monitor for floaters and glaucoma; plan for vitrectomy if vision declines. Mechanism: address vitreous amyloid and pressure early. PMC

16. Cardiac device evaluation when indicated—pacemakers/defibrillators for conduction disease or ventricular arrhythmias. Mechanism: prevents syncope or sudden death in advanced cardiac involvement. AHA Journals

17. Heat avoidance and cooling strategies—limit neuropathic pain flares and orthostatic symptoms aggravated by heat. Mechanism: reduces vasodilation and small-fiber pain triggers. NCBI

18. Smoking and excess alcohol avoidance—supports neuropathy and cardiac health. Mechanism: reduces neurotoxic and cardiotoxic stressors. NCBI

19. Vaccinations & infection prevention—illness can worsen autonomic instability and nutrition. Mechanism: reduces decompensation triggers. NCBI

20. Psychosocial support & peer groups—reduces isolation, improves coping, and supports adherence. Mechanism: improves quality of life and treatment continuity. NCBI

---

Drug treatments

Important: Dosing and suitability must be individualized by your clinician, especially with heart or kidney disease.

1. Tafamidis (TTR stabilizer) — Dose: 61 mg orally once daily (bioequivalent to 80 mg meglumine). Purpose: slows heart failure events and death in ATTR cardiomyopathy. Mechanism: binds TTR and stabilizes the tetramer, preventing dissociation. Side effects: generally well tolerated; occasional GI symptoms. ICER+2New England Journal of Medicine+2

2. Patisiran (siRNA—TTR silencer) — Dose: 0.3 mg/kg IV every 3 weeks. Purpose: improves neuropathy and quality of life in hereditary ATTR polyneuropathy. Mechanism: hepatic TTR mRNA knock-down via RNA interference. Side effects: infusion-related reactions; needs vitamin A supplementation. FDA Access Data+1

3. Vutrisiran (siRNA—TTR silencer) — Dose: 25 mg SC every 3 months. Purpose: improves neuropathy and (in HELIOS-B) reduced death and CV events in ATTR-CM. Mechanism: subcutaneous GalNAc-siRNA targeting hepatic TTR. Side effects: injection-site reactions; monitor vitamin A. FDA Access Data+2FDA Access Data+2

4. Inotersen (antisense oligonucleotide—TTR silencer) — Dose: 284 mg SC weekly. Purpose: slows neuropathy progression. Mechanism: antisense TTR mRNA degradation in the liver. Side effects: thrombocytopenia and glomerulonephritis—requires frequent platelet/renal monitoring. New England Journal of Medicine+2FDA Access Data+2

5. Eplontersen (ligand-conjugated antisense, “Wainua”) — Dose: 45 mg SC monthly (auto-injector). Purpose: improves neuropathy measures and quality of life (NEURO-TTRansform). Mechanism: TTR antisense with GalNAc targeting. Side effects: injection-site reactions; lab monitoring per label. JAMA Network+2FDA Access Data+2

6. Diflunisal (off-label TTR stabilizer; NSAID) — Typical studied dose: 250 mg orally twice daily. Purpose: slowed neuropathy progression in FAP over 2 years. Mechanism: binds TTR thyroxine pocket to stabilize tetramer. Side effects: GI bleeding, kidney injury, fluid retention—avoid in many cardiac/renal patients. PMC

7. Doxycycline + TUDCA (off-label adjunct) — Dose examples in studies: doxycycline 100 mg/day + TUDCA 250 mg three times daily. Purpose: exploratory stabilization of disease in small studies. Mechanism: doxycycline may disrupt fibrils; TUDCA acts as a chemical chaperone. Side effects: photosensitivity, GI upset; evidence remains preliminary. PubMed+1

8. Loop diuretics (symptom relief in heart failure) — Dose: individualized (e.g., furosemide). Purpose: reduce edema and breathlessness in ATTR-CM. Mechanism: renal sodium/water excretion. Side effects: electrolyte loss, kidney effects—requires monitoring. AHA Journals

9. Mineralocorticoid receptor antagonists (HF care) — Dose: individualized. Purpose: edema and neurohormonal modulation in HF; caution with kidney function. Mechanism: blocks aldosterone. Side effects: high potassium, renal issues. AHA Journals

10. Beta-blockers (selected patients) — Purpose: rate control in atrial arrhythmias or ischemia; use cautiously as some patients with amyloid do not tolerate high doses. Mechanism: sympathetic blockade. Side effects: fatigue, hypotension. AHA Journals

11. Anticoagulants for atrial fibrillation — Purpose: stroke prevention when AF occurs (common in amyloid cardiomyopathy). Mechanism: reduces thrombosis risk. Side effects: bleeding risks. AHA Journals

12. Midodrine or droxidopa (for refractory orthostatic hypotension) — Purpose: raise standing blood pressure when non-drug steps fail. Mechanism: vasoconstriction or norepinephrine precursor. Side effects: supine hypertension, tingling, headache—use with compression and head-of-bed elevation. AAFP

13. Neuropathic pain agents (duloxetine, gabapentinoids, TCAs—carefully) — Purpose: reduce burning pain; choose agents mindful of autonomic side effects. Mechanism: central pain modulation. Side effects: sedation, dizziness, anticholinergic effects (TCAs). NCBI

14. Topical lidocaine or capsaicin — Purpose: focal neuropathic pain relief. Mechanism: local sodium channel blockade or TRPV1 desensitization. Side effects: local irritation. NCBI

15. Vitamin A supplementation with TTR-silencing drugs — Purpose: prevent deficiency because hepatic TTR carries retinol-binding protein. Mechanism: replaces reduced retinol transport. Side effects: watch for hypervitaminosis A. FDA Access Data

16. Treat diarrhea (e.g., loperamide) and gastroparesis support — Purpose: symptom control in autonomic GI involvement. Mechanism: slows gut transit; dietary changes plus prokinetics per clinician. Side effects: constipation or QT effects (with some prokinetics). NCBI

17. Eyelowering drops for glaucoma — Purpose: protect optic nerve if pressure rises with ocular amyloid. Mechanism: reduce aqueous production or increase outflow. Side effects: vary by class. PMC

18. Arrhythmia management (antiarrhythmics) — Purpose: control AF/flutter or ventricular arrhythmias; often combined with device therapy. Mechanism: varies by drug. Side effects: drug-specific; careful monitoring needed. AHA Journals

19. Iron and nutrition support when deficient — Purpose: treat anemia and frailty that worsen symptoms. Mechanism: corrects deficiencies. Side effects: GI upset (oral iron). NCBI

20. Vaccination (influenza, pneumococcal per guidelines) — Purpose: reduce decompensation from infections in frail patients. Mechanism: immune protection. Side effects: usual vaccine reactions. NCBI

---

Dietary molecular supplements

1. Alpha-lipoic acid — studied mainly in diabetic neuropathy for pain and function; not ATTR-specific. Typical doses used in studies: 300–600 mg/day. Function/mechanism: antioxidant and mitochondrial support; mixed evidence. BioMed Central

2. Omega-3 fatty acids — general heart health; may help triglycerides and inflammation. Dose: ~1–2 g/day EPA+DHA under clinician advice. Mechanism: anti-inflammatory lipid mediators; not disease-modifying for ATTR. AHA Journals

3. EGCG (green tea extract) — lab and animal work show TTR-stabilizing/anti-amyloid effects; human cardiac case series suggest possible slowing, but robust trials are lacking. Dose: variable in supplements; monitor for liver toxicity. Mechanism: binds TTR and may disrupt fibrils. ScienceDirect+1

4. Curcumin — mouse models and in-vitro data suggest TTR binding and amyloid inhibition; human evidence is preliminary. Dose: varies (often 500–1000 mg/day of curcuminoids); watch drug interactions. Mechanism: hydrophobic pocket binding; anti-amyloid effects. Nature+1

5. Resveratrol/pterostilbene — preclinical and computational studies show inhibition of V30M TTR fibrillization; human data are lacking. Dose: varies widely. Mechanism: phenolic binding to TTR; antioxidant actions. American Chemical Society Publications

6. Coenzyme Q10 — general mitochondrial support in cardiomyopathy; ATTR-specific evidence lacking. Dose: 100–300 mg/day typical. Mechanism: electron transport/antioxidant. AHA Journals

7. Vitamin A (with silencers) — only under clinician guidance when on patisiran/vutrisiran/inotersen/eplontersen. Dose: per clinician, avoids deficiency. Mechanism: replaces retinol transport lost with TTR suppression. FDA Access Data

8. Vitamin D — general bone and muscle support; screen and replete if deficient. Dose: per labs. Mechanism: bone-muscle health; not disease-modifying. NCBI

9. B-complex (B12/folate) — correct deficiencies that worsen neuropathy; treat only when low. Dose: per labs. Mechanism: supports myelin and nerve metabolism. NCBI

10. TUDCA (with doxycycline protocols) — used in small exploratory ATTR studies; not standard of care. Dose in studies: 250 mg three times daily. Mechanism: chemical chaperone that may reduce ER stress and fibril toxicity. PubMed

Note: none of the supplements above are proven to replace approved ATTR therapies. Please review all supplements with your clinician to avoid interactions.

---

Immunity-booster / regenerative / stem-cell drugs

There are no approved immune-booster or stem-cell drugs for ATTRv. Research is moving toward gene editing and better silencers. Below are research directions or supportive concepts—not recommendations to self-use.

1. Next-generation gene editing (research) — early clinical reports and editorials suggest potential for one-time TTR knockdown, but this is investigational. Mechanism: CRISPR-based editing of hepatic TTR. Dose: research protocols only. New England Journal of Medicine

2. Enhanced siRNA/ASO platforms — newer GalNAc-conjugated agents (e.g., vutrisiran, eplontersen) deliver stronger, sustained TTR suppression with infrequent dosing, and now include cardiomyopathy indications. Mechanism: potent hepatic TTR silencing. Dose: per labels. FDA Access Data+1

3. Combination therapy trials — studies are exploring stabilizer + silencer or silencer-to-stabilizer switches to deepen control. Mechanism: reduces production and increases stability simultaneously. Dose: trial-based. PMC

4. Regenerative rehab — exercise-driven neuroplasticity and strength can partially restore function despite nerve damage. Mechanism: training-induced adaptations. Dose: supervised programs. PubMed

5. Autonomic support strategies — compression + head-of-bed elevation + fluids can “restore” standing BP without drugs. Mechanism: hemodynamic support. Dose: daily routines. AAFP

6. Nutritional optimization — targeted protein/calorie support counters catabolism and frailty in systemic disease. Mechanism: improves resilience and recovery potential. NCBI

---

Surgeries/procedures

1. Liver transplantation (LT) — historically the standard for early-onset V30M because the liver makes most circulating mutant TTR. Outcomes are best in early-onset V30M; benefit is less consistent in other mutations and late-onset disease. Modern practice often prefers gene-silencing drugs, but LT may still be considered in select cases. Lippincott Journals+1

2. Heart transplantation (± combined heart-liver) — for advanced cardiomyopathy in carefully selected patients. Decisions depend on age, comorbidities, and access to disease-modifying drugs. PMC

3. Carpal tunnel release — relieves nerve compression; surgeons may send tenosynovium for amyloid typing, which can flag systemic disease earlier. AHA Journals

4. Pars plana vitrectomy — for dense vitreous amyloid causing major floaters and visual loss; recurrence can happen, so close glaucoma follow-up is needed. Nature+1

5. Cardiac devices (pacemaker/defibrillator) — for conduction disease or ventricular arrhythmias. Improves safety but does not treat amyloid itself. AHA Journals

---

Practical prevention tips

Because the mutation is fixed, “prevention” means slowing complications and catching disease early.

1. Get genetic counseling/testing in affected families; 2) start regular surveillance (neurology, cardiology, eye) before symptoms; 3) keep vaccinations current; 4) follow low-sodium diet if heart involved; 5) practice foot care daily; 6) use compression garments if you have orthostatic symptoms; 7) avoid dehydration and heat; 8) report carpal tunnel symptoms early; 9) maintain exercise with balance/strength work; 10) review supplements/OTC with your clinician to avoid harm. BioMed Central+2AHA Journals+2

---

When to see a doctor

See a clinician now if you have: new numbness/burning pain in feet with a family history of ATTR; repeated fainting/dizziness; unexplained weight loss or diarrhea; shortness of breath or leg swelling; or dense floaters and vision changes. Seek urgent care for chest pain, fainting, black stools or vomiting blood (possible NSAID bleeding), or sudden weakness. NCBI

---

What to eat and what to avoid

Eat: 1) balanced meals with adequate protein; 2) fruits/vegetables for micronutrients; 3) whole grains for bowel health; 4) healthy fats (olive oil, nuts, fish); 5) small frequent meals if you get post-meal dizziness. Avoid/limit: 6) high sodium if you have edema/heart symptoms; 7) excess alcohol; 8) very large, salty restaurant meals; 9) energy drinks that can worsen palpitations; 10) unreviewed supplements that may interact with therapy. AHA Journals

---

FAQs

1) Is ATTRV30M always symptomatic?
No. Not all carriers get sick; penetrance varies by family, age, and region. Regular surveillance is key. PMC

2) What is the first sign?
Often numbness or burning in the feet; sometimes carpal tunnel or GI/autonomic symptoms. NCBI

3) How is the diagnosis confirmed?
By TTR gene testing plus biopsy or noninvasive cardiac scintigraphy (with AL ruled out). NCBI+1

4) Do nerve tests help?
Yes. Nerve studies and autonomic tests show extent and pace of neuropathy. NCBI

5) Are there effective medicines?
Yes. Silencers (patisiran, vutrisiran, inotersen, eplontersen) and stabilizers (tafamidis; diflunisal—off-label) improve outcomes in the right patients. New England Journal of Medicine+4New England Journal of Medicine+4PubMed+4

6) Can medicines help the heart?
Tafamidis reduces deaths and hospitalizations in ATTR-CM; vutrisiran has shown reductions in death and CV events in HELIOS-B. New England Journal of Medicine+1

7) Do I still need vitamin A?
If you are on a silencer, yes—your team will guide safe dosing. FDA Access Data

8) Is liver transplant still used?
Much less often, but early-onset V30M cases may be considered individually; outcomes vary by mutation and timing. Lippincott Journals

9) Can surgery help my vision?
Yes. Vitrectomy can clear vitreous amyloid, but it can recur; glaucoma monitoring is important. Nature

10) What if I have carpal tunnel?
Release surgery can help symptoms and, when tissue is tested, may reveal amyloid that prompts earlier diagnosis. AHA Journals

11) How do doctors track the heart?
With ECG, echocardiogram, cardiac MRI, and 99mTc-PYP scans, plus heart-failure labs and rhythm monitoring. JACC

12) Can exercise make things worse?
Gentle, supervised aerobic + balance + strength training is usually helpful; adjust if you get dizzy on standing. PubMed

13) Are supplements a cure?
No. Some (EGCG, curcumin) show lab/animal anti-amyloid effects but are not substitutes for approved drugs. ScienceDirect

14) What about new treatments?
New silencers and gene-editing approaches are in development; speak with a center experienced in amyloidosis about trials. New England Journal of Medicine

15) What is the outlook?
Outcomes are improving with earlier diagnosis and modern therapy, especially when the heart is protected and neuropathy is treated early. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 28, 2025.